Innate Pharma (IPHA) Total Debt (2017 - 2025)
Innate Pharma's (IPHA) quarterly Total Debt came in at $26.3 million in Q4 2025, down 20.67% YoY from $33.1 million in Q4 2024, and down 14.12% on a QoQ basis from $30.6 million in Q2 2025.
Innate Pharma (IPHA) Total Debt (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Total Debt data on file, last reported at $26.3 million in Q4 2025.
- Quarterly Total Debt fell 20.67% year-over-year to $26.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $26.3 million (down 20.67% YoY) and the FY2025 annual result came in at $36.5 million, down 13.92% from the prior year.
- Total Debt eased to $26.3 million in Q4 2025, from $30.6 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $67.8 million in Q2 2022 to a low of $19.9 million in Q2 2021.
- A 5-year average of $39.7 million and a median of $40.6 million in 2023 frame the typical range for Total Debt.
- Annual changes were most pronounced in 2021 — Total Debt sank 99.89% — and 2022, when it jumped 241.26%.
- Tracing IPHA's Total Debt over 5 years: stood at $50.6 million in 2021, then dropped by 14.85% to $43.1 million in 2022, then fell by 0.43% to $42.9 million in 2023, then fell by 22.84% to $33.1 million in 2024, then fell by 20.67% to $26.3 million in 2025.
- The last three Total Debt figures came in at $26.3 million (Q4 2025), $30.6 million (Q2 2025), and $33.1 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.34 Bn |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | 26.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 26.28 Mn |
| Jun 30, 2025 | 30.60 Mn |
| Dec 31, 2024 | 33.12 Mn |
| Jun 30, 2024 | 38.23 Mn |
| Dec 31, 2023 | 42.92 Mn |
| Jun 30, 2023 | 44.27 Mn |
| Dec 31, 2022 | 43.11 Mn |
| Jun 30, 2022 | 67.82 Mn |
| Dec 31, 2021 | 50.62 Mn |
| Jun 30, 2021 | 19.87 Mn |
| Dec 31, 2020 | 22.76 Mn |
| Jun 30, 2020 | 18.82 Bn |
| Dec 31, 2019 | 20.72 Mn |
| Dec 31, 2018 | 6.49 Mn |
| Dec 31, 2017 | 6.90 Mn |